Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis

BACKGROUND: Ocrelizumab was found to decrease brain atrophy rate in primary progressive multiple sclerosis (PPMS), but no data are currently available on the effect of ocrelizumab on retinal layer thicknesses in the PPMS population. OBJECTIVE: To assess retinal layer changes in ocrelizumab-treated P...

Descripción completa

Detalles Bibliográficos
Autores principales: Miscioscia, Alessandro, Puthenparampil, Marco, Miante, Silvia, Pengo, Marta, Rinaldi, Francesca, Perini, Paola, Gallo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467948/
https://www.ncbi.nlm.nih.gov/pubmed/35648233
http://dx.doi.org/10.1007/s00415-022-11183-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467948/
https://www.ncbi.nlm.nih.gov/pubmed/35648233
http://dx.doi.org/10.1007/s00415-022-11183-y

Ejemplares similares